Evidence map›Paper›PMID 34243015›Full record

ArticleTranslational oncology2021

The significance of SMARCB1 in the pathogenesis of renal cell carcinoma with rhabdoid features.

Yi-Wen Wang, Hsiang-Lin Song, Cheng-Yao Chiang, Hong-Fang Song, Hong-Yi Chang, Chien-An Chu, Yih-Lin Tuan, Kun-Hao Tsai, Yin-Chien Ou, Nan-Haw Chow and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yi-Wen WangDepartments of Pathology, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Hsiang-Lin SongDepartment of Pathology, National Cheng Kung University Hospital, Tainan, TAIWAN.
Cheng-Yao ChiangDepartments of Pathology, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Hong-Fang SongInstitute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Hong-Yi ChangDepartment of Biotechnology and Food Technology, College of Engineering, Southern Taiwan University of Science and Technology, Tainan, TAIWAN.
Chien-An ChuDepartments of Pathology, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Yih-Lin TuanInstitute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Kun-Hao TsaiInstitute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Yin-Chien OuDepartments of Urology, College of Medicine, National Cheng Kung University, Tainan, TAIWAN.
Nan-Haw ChowDepartments of Pathology, College of Medicine, National Cheng Kung University, Tainan, TAIWAN; Department of Pathology, National Cheng Kung University Hospital, Tainan, TAIWAN; Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, TAIWAN. Electronic address: chownh@mail.ncku.edu.tw.
Yuh-Shyan TsaiDepartments of Urology, College of Medicine, National Cheng Kung University, Tainan, TAIWAN. Electronic address: youh@mail.ncku.edu.tw.
National Cheng Kung University · TWNational Cheng Kung University Hospital · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal cell carcinoma with rhabdoid features (RCC-RF) is an aggressive histologic variant in the adults and is usually unresponsive to standard chemotherapy.

methodsExpression of SMARCB1/INI1 was examined in primary RCC-RF (n = 5). Stable INI1 with/without prostaglandin E2 receptor 1 (EP1) knockdown cell lines were created in the ACHN and 786-O RCC cell lines and measured for epidermal growth factor receptor (EGFR)-related signaling pathways. Chemosensitivity to targeted drugs in vitro was tested after knocking down of INI1 in both cell lines. The outcome of co-targeting of INI1 and EP1 in RCC was examined using a tumorigenicity assay.

resultsExpression of INI1 was markedly reduced at both transcriptional and translational levels in primary RCC-RF. Immunohistochemical expression of INI1 protein was lost in the nuclei of rhabdoid cells compared with conventional RCC (n = 8). Using two cell lines with different genetic background, we showed that knocking down of INI1 activates the EGFR signaling with up-regulated AKT and ERK pathways and sensitizes cancer cells to Erlotinib treatment in vitro. However, cell-line dependent effects were also demonstrated with reference to impact of INI1 or EP1 on cell growth, migration and response to Gefitinib or Everolimus treatment in vitro.

conclusionInactivation of INI1 may play a role in the pathogenesis of RCC-RF. Erlotinib is recommended in the management of patients with INI1-related RCC.

Indexed as

Epidermal growth factor receptorErlotinibRenal cell carcinomaRhabdoid differentiationSMARCB1

Identifiers

PMID34243015
PMCPMC8273225
OpenAlexW3179646452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.